Comparing Treatment Outcomes of Antiretroviral Therapy in HIV-1 and HIV-2 Infected Patients, in Bamako, Mali.

Current findings of infectious diseases Pub Date : 2018-01-01 Epub Date: 2018-11-26
Aboubacar Alassane Oumar, Yacouba Cissoko, Issa Konaté, Adam Kane, Jean Paul Dembélé, Mamadou Cissé, Robert Leo Murphy, Jean Cyr Yombi, Moussa Seydi, Sounkalo Dao, Mamoudou Maiga
{"title":"Comparing Treatment Outcomes of Antiretroviral Therapy in HIV-1 and HIV-2 Infected Patients, in Bamako, Mali.","authors":"Aboubacar Alassane Oumar,&nbsp;Yacouba Cissoko,&nbsp;Issa Konaté,&nbsp;Adam Kane,&nbsp;Jean Paul Dembélé,&nbsp;Mamadou Cissé,&nbsp;Robert Leo Murphy,&nbsp;Jean Cyr Yombi,&nbsp;Moussa Seydi,&nbsp;Sounkalo Dao,&nbsp;Mamoudou Maiga","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>HIV-2 leads to a less-severe disease than HIV-1 but is known to be resistant to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). We goaled to evaluate the clinical and biological outcomes of HIV-1 and HIV-2 infected-patients under Antiretroviral Therapy (ART) that do not include NNRTIs.</p><p><strong>Methods: </strong>This is a case-control study of 100 participants (half in each group) to measure the frequency of clinical and biological adverse effects, and disease outcome at 6 and 12 months of treatment (M6 and M12) We included.</p><p><strong>Results: </strong>Opportunistic infections were more frequent in HIV-1 infected patients with 82% when compared to HIV-2, 68%. However, the prevalence of treatment adverse events was slightly higher in HIV-2 infected patients. The average increase of CD4 cell count at M6 of treatment was 139.93 and 159.41 cells/mm3, for HIV-2 and HIV-1 groups respectively, and at 153 and 217 cells/mm3, at M12 for HIV-2 and HIV-1 respectively. A total of nine HIV-2 and six HIV-1 deaths were reported during the study.</p><p><strong>Conclusion: </strong>This study has shown that ART regimens that do not include NNRTIs are effective equally in the treatment of HIV-1 and HIV-2 infections. Nevertheless, we recommend regular and continuous laboratory monitoring for all HIV treated patients.</p>","PeriodicalId":92498,"journal":{"name":"Current findings of infectious diseases","volume":"2018 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322838/pdf/nihms-1002585.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current findings of infectious diseases","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/11/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: HIV-2 leads to a less-severe disease than HIV-1 but is known to be resistant to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). We goaled to evaluate the clinical and biological outcomes of HIV-1 and HIV-2 infected-patients under Antiretroviral Therapy (ART) that do not include NNRTIs.

Methods: This is a case-control study of 100 participants (half in each group) to measure the frequency of clinical and biological adverse effects, and disease outcome at 6 and 12 months of treatment (M6 and M12) We included.

Results: Opportunistic infections were more frequent in HIV-1 infected patients with 82% when compared to HIV-2, 68%. However, the prevalence of treatment adverse events was slightly higher in HIV-2 infected patients. The average increase of CD4 cell count at M6 of treatment was 139.93 and 159.41 cells/mm3, for HIV-2 and HIV-1 groups respectively, and at 153 and 217 cells/mm3, at M12 for HIV-2 and HIV-1 respectively. A total of nine HIV-2 and six HIV-1 deaths were reported during the study.

Conclusion: This study has shown that ART regimens that do not include NNRTIs are effective equally in the treatment of HIV-1 and HIV-2 infections. Nevertheless, we recommend regular and continuous laboratory monitoring for all HIV treated patients.

在马里巴马科比较HIV-1和HIV-2感染患者抗逆转录病毒治疗的治疗结果
背景:HIV-2导致的疾病不像HIV-1那么严重,但已知对非核苷类逆转录酶抑制剂(NNRTIs)具有耐药性。我们的目标是评估接受抗逆转录病毒治疗(ART)的HIV-1和HIV-2感染患者的临床和生物学结果,不包括nnrti。方法:这是一项100名参与者(每组一半)的病例对照研究,以测量临床和生物学不良反应的频率,以及我们纳入的治疗6个月和12个月(M6和M12)的疾病结局。结果:机会性感染在HIV-1感染者中发生率为82%,而在HIV-2感染者中发生率为68%。然而,在HIV-2感染患者中,治疗不良事件的发生率略高。HIV-2和HIV-1组在治疗M6时CD4细胞计数平均增加139.93和159.41个细胞/mm3, HIV-2和HIV-1组在治疗M12时CD4细胞计数平均增加153和217个细胞/mm3。研究期间共报告了9例HIV-2和6例HIV-1死亡。结论:这项研究表明,不包括nnrti的ART方案在治疗HIV-1和HIV-2感染方面同样有效。然而,我们建议对所有接受艾滋病毒治疗的患者进行定期和持续的实验室监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信